PARP
9 articles
PharmacologyBiochemical Pharmacology
Platinum agent traps DNA AP sites, bypassing APE1 and cisplatin resistance
- Benzoquinoplatin, a benzoquinoline carrying a monofunctional platinum(II) group, covalently traps abasic DNA sites so APE1 can no longer cleave them; the enzyme itself is not inhibited.
- In cancer cells it caused sustained DNA-damage signalling, cell cycle arrest and apoptosis, and was far more potent than cisplatin.
- It stayed active in cisplatin-resistant cells and slowed resistant xenograft growth.
- Combining it with PARP inhibition was synergistic.
Trapping AP sites sidesteps the usual enzyme-inhibitor problem, but a monofunctional platinum adduct raises the selectivity question: what keeps it from reacting with other DNA sites, proteins or thiols? I'd want repair-deficient versus proficient isogenic pairs, normal-cell toxicity and some exposure data before believing the xenograft result. The PARP synergy is plausible, yet it may also add marrow toxicity.
Medicinal ChemistryJournal of Medicinal Chemistry
Benzofused carboxamide D13 combines PARP inhibition and tubulin colchicine-site binding, showing strong antitumor activity in cells and a breast cancer xenograft
- Benzofused heterocyclic carboxamides were designed as single molecules hitting both PARP and the tubulin colchicine-binding site, aiming to counter tumor heterogeneity and resistance.
- SAR work led to D13, which showed low-nanomolar antiproliferative activity across several cancer lines with good selectivity over normal cells, inhibited PARP1/2, and blocked tubulin polymerization.
- D13 caused G2/M arrest, DNA damage and apoptosis, limited migration and tube formation, and in an MDA-MB-231 xenograft outperformed veliparib, phenstatin and their combination with good tolerability.
Dual PARP/colchicine-site agents are tough to balance: the two pharmacophores want different shapes, so I'd check that D13 isn't just a potent tubulin binder with incidental PARP activity. Key controls are PARP-null or BRCA-proficient cells, and a tubulin-inactive analog. Also, tubulin toxicity could erode the therapeutic window that PARP inhibitors normally enjoy.
Medicinal ChemistryJournal of Medicinal Chemistry
Dual PARP/BRD4 inhibitor D6 curbs tumor growth in breast cancer xenograft
- Because BRD4 inhibition weakens homologous recombination repair, the authors built dual PARP/BRD4 inhibitors to make cancer cells more vulnerable to PARP blockade.
- SAR optimization yielded D6, which inhibits both PARP1 and BRD4 in the low-nanomolar range and suppresses proliferation, colony formation and metastasis-related phenotypes in breast and pancreatic cancer cells.
- D6 downregulates the BRD4-cJUN-CCL2 axis, reducing macrophage recruitment and macrophage-driven invasion.
- In a breast cancer xenograft, D6 slowed tumor growth without evident toxicity.
Two targets in one molecule looks elegant on paper, but balance is the hard part. Can one exposure hold both PARP1 and BRD4 engaged at tolerable doses, or does BRD4 occupancy drive toxicity? Before calling the pharmacophore merge a win, I need D6 compared with a PARP inhibitor plus BET inhibitor combination, and its selectivity across other bromodomains.
Medicinal ChemistryJournal of Medicinal Chemistry (ACS)
Replacing saruparib's carboxamide yields an oral, brain-penetrant PARP1-selective inhibitor
- Aimed at CNS malignancies, the program replaced the carboxamide of saruparib with a series of heterocycles, targeting PARP1 over PARP2 to limit haematological toxicity.
- Caco-2 efflux, rather than the usual MDR1-MDCK assay, was used as a progression filter to select compounds with good unbound brain exposure.
- The lead compound was orally bioavailable and caused tumour regression in xenografts at a low dose, with a projected low clinical dose.
Swapping the primary carboxamide is a bold move, since that group anchors the nicotinamide pocket, and the heterocycles evidently kept the binding. The more useful lesson is the filter: if Caco-2 efflux predicts unbound brain exposure better than MDR1-MDCK, plenty of CNS programs may be discarding good compounds.
Medicinal ChemistryJournal of Medicinal Chemistry (ACS)
Oral POLQ polymerase inhibitors regress BRCA2-null tumors with olaparib
- POLQ drives microhomology-mediated end joining, making it a synthetic-lethal target in homologous-recombination-deficient cancers.
- Optimizing a weak biochemical hit gave benzimidazole/purine inhibitors; compound 37 is potent, selective and orally active.
- In BRCA2-deficient DLD-1 cells it was antiproliferative and boosted olaparib, with no effect in HR-proficient cells; chronic oral dosing with olaparib regressed xenografts.
A polymerase-domain inhibitor that is both oral and selective for the HR-deficient setting is what this target has been missing. The HR-proficient null result is the key control, so I'd now look at resistance and how it stacks against the helicase-domain approaches.
Medicinal ChemistryJournal of Medicinal Chemistry (ACS)
New Dual-Acting Molecules Pair PARP Inhibition with Ferroptosis to Fight TNBC
- Medicinal chemists designed single small molecules combining PARP inhibition with GPX4 inhibition, pairing DNA-repair blockade with ferroptosis induction in one compound rather than as a drug combination.
- Structure-activity relationship work identified a new dual-acting chemotype optimized for potency against both targets.
- Lead compounds showed antitumor activity in triple-negative breast cancer models, supporting the dual-mechanism approach as a possible way to broaden PARP inhibitor efficacy.
Most TNBC is BRCA-wild-type, so PARP monotherapy has nowhere to go without synthetic lethality — pairing it with GPX4 inhibition to force ferroptosis is a real way around that, not just an add-on. The tougher ask is holding potency at two unrelated targets in one scaffold without MW/logP creeping past drug-like — if they pulled that off cleanly, it's more interesting than the biology.
Medicinal ChemistryJournal of Medicinal Chemistry (ACS)
Dual PARP-1/CK2α Inhibitors Aim Beyond HRD-Restricted Tumors
- Researchers designed a new class of small molecules built on a benzothieno[3,2-d]pyrimidin-4(1H)-one scaffold that simultaneously inhibits PARP-1 and casein kinase 2 alpha (CK2α).
- PARP-1 inhibitors typically benefit only tumors with homologous recombination deficiency (HRD); pairing PARP-1 blockade with CK2α inhibition, a kinase linked to DNA damage response and cell survival signaling, is proposed to extend efficacy to HRD-proficient tumors and limit metastatic spread.
- Structure-activity relationship exploration identified substituents on the tricyclic core that support potent, balanced binding at both targets.
- In cellular and tumor models, the dual inhibitors reportedly show antiproliferative and anti-metastatic activity independent of HRD status, supporting dual-target inhibition as a route beyond BRCA-mutant-restricted use.
Holding balanced dual-target SAR on one scaffold is the real difficulty here, not the headline claim — PARP-1's nicotinamide pocket and CK2α's ATP site are shaped nothing alike, so a substituent you add to hold potency at one target can quietly tank the other. I'd want the full SAR table, not just the lead actives, before believing that balance survives further optimization. The real payoff isn't PARP-1 potency itself, it's escaping the BRCA/HRD ceiling — another single-target PARP inhibitor chasing olaparib's lane is a hard sell, but HRD-independent activity actually opens new patient populations. The tricyclic benzothienopyrimidinone core gives usable vectors for dual substitution, though fusing two pharmacophores tends to inflate MW and logP fast. Next data I need: kinome-wide selectivity beyond CK2α, in vivo therapeutic window, and whether the anti-metastatic signal holds up against a PARP-1-only comparator.
Medicinal ChemistryJournal of the American Chemical Society (ACS)
Machine-Learning Screen of 5M Candidates Yields Light-Activated PARP1 Inhibitors
- Combined protein–ligand docking, ML force fields, quantum chemistry, and free-energy perturbation (FEP) to screen roughly 5 million hypothetical photoactive PARP1 ligands.
- Docking identified candidates with differential PARP1 binding between light-exposed and dark states; ML force fields and QM calculations predicted pKa, absorption spectra, and thermal half-lives, while graph-based surrogate models screened the remaining library.
- Excited-state nonadiabatic dynamics simulations (with ML force fields) estimated photoswitching quantum yields; FEP refined binding-affinity predictions for top hits.
- Prioritized a small set of synthetically accessible candidates combining red-shifted absorption (favoring deeper tissue penetration), therapeutically suitable thermal half-lives, and light/dark-selective PARP1 binding.
- Predictions were experimentally validated, demonstrating an end-to-end computational-to-experimental pipeline for designing light-activated (photopharmacological) cancer therapeutics.
Five million virtual candidates funneled down to a handful that actually work is the real story — that pipeline (docking → ML force fields → QM → nonadiabatic dynamics → FEP) is doing what a med chem team's SAR intuition used to do by hand, just faster and across chemical space no bench chemist would ever hand-explore. The binding-mode hypothesis is straightforward: a photoswitch appended to (presumably) a nicotinamide-mimetic PARP1 pharmacophore toggles pocket occupancy between light and dark isomers, so "selectivity" here means spatiotemporal control over tumor tissue, not isoform selectivity against PARP2/tankyrases — a different axis entirely from what olaparib or niraparib were ever optimized for. Red-shifted absorption for tissue penetration plus a therapeutically workable thermal half-life are the tractability bottlenecks that usually kill photopharmacology leads, so getting synthetically accessible hits past both, and into validated wet-lab data, is the genuinely notable part.
Medicinal ChemistryJournal of Medicinal Chemistry (ACS)
Silencing PARP1 at the Gene Level: A G-Quadruplex-Binding Small Molecule Sidesteps PARP Inhibitor Toxicity
- Rather than inhibiting or trapping the PARP1 enzyme like approved PARP inhibitors (PARPis), researchers targeted the PARP1 gene promoter itself to shut down PARP1 production at the transcriptional level, aiming to avoid the hematologic toxicity and resistance mechanisms associated with PARPi-mediated PARP1 trapping.
- The promoter region forms a non-canonical (3+1) hybrid G-quadruplex structure distinguished by an adenine bulge, a distinctive DNA fold not previously exploited as a drug target.
- Combining computational modeling with biophysical characterization, the team identified a small molecule that selectively engages this unusual G-quadruplex architecture.
- In multiple myeloma cells, the compound reduced PARP1 expression, disrupted downstream DNA repair signaling, and triggered DNA damage-associated apoptosis.
- Healthy blood cells were largely spared, pointing to a possible therapeutic window distinct from conventional PARP inhibitor toxicity profiles.
The part that gets me: attacking PARP1 at the promoter instead of the active site. Every PARPi on the market — olaparib, niraparib, talazoparib — works by trapping or inhibiting the protein; the hematologic toxicity and trapping-driven resistance are baked into that mechanism. Silencing transcription via a G-quadruplex sidesteps the whole liability profile, at least on paper. That said, G4-targeting ligands are a rough class to work in — selectivity across the thousands of quadruplex-forming sequences in the genome is the perennial failure mode, not potency. And this (3+1) hybrid fold with an adenine bulge is a genuinely novel pocket, which cuts both ways: interesting SAR territory, but no playbook to lean on. Still early — a validated hit in MM cells, not a lead, let alone a candidate. Worth watching, not betting on yet.